Clinical Trial Detail

NCT ID NCT02301039
Title A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Sarcoma Alliance for Research through Collaboration
Indications

malignant peripheral nerve sheath tumor

liposarcoma

medulloblastoma

synovial sarcoma

leiomyosarcoma

fibrous histiocytoma

Therapies

Pembrolizumab

Age Groups: adult child

No variant requirements are available.